Brand Name | Status | Last Update |
---|---|---|
cotellic | New Drug Application | 2024-11-18 |
Expiration | Code | ||
---|---|---|---|
COBIMETINIB FUMARATE, COTELLIC, GENENTECH INC | |||
2029-10-28 | ODE-416 | ||
2026-01-28 | PED | ||
2025-10-28 | I-902 | ||
2025-07-28 | M-278 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 4 | 2 | — | — | — | 6 |
Non-small-cell lung carcinoma | D002289 | — | — | 2 | 2 | — | — | — | 3 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 1 | — | — | — | 2 |
Multiple myeloma | D009101 | — | C90.0 | 1 | 2 | — | — | — | 2 |
Lung neoplasms | D008175 | — | C34.90 | 1 | 2 | — | — | — | 2 |
Histiocytosis | D015614 | HP_0100727 | — | — | 2 | — | — | — | 2 |
Gastrointestinal neoplasms | D005770 | — | C26.9 | 1 | 1 | — | — | — | 1 |
Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | — | 1 | — | — | — | 1 |
Urinary bladder neoplasms | D001749 | — | C67 | — | 1 | — | — | — | 1 |
Biliary tract neoplasms | D001661 | — | C24.9 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 7 | — | — | — | — | 7 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 3 | — | — | — | — | 3 |
Adenocarcinoma | D000230 | — | — | 2 | — | — | — | — | 2 |
Pancreatic ductal carcinoma | D021441 | — | — | 1 | — | — | — | — | 1 |
Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Prostatic neoplasms | D011471 | — | C61 | 1 | — | — | — | — | 1 |
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Carcinoma | D002277 | — | C80.0 | 1 | — | — | — | — | 1 |
Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
Sarcoma | D012509 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Cobimetinib |
INN | cobimetinib |
Description | Cobimetinib is a member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. It has a role as an EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor and an antineoplastic agent. It is a member of piperidines, a N-acylazetidine, a tertiary alcohol, an aromatic amine, a secondary amino compound, a difluorobenzene and an organoiodine compound. It is a conjugate base of a cobimetinib(1+). |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors: tyrosine kinase inhibitors; MEK (MAPK kinase) inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | O=C(c1ccc(F)c(F)c1Nc1ccc(I)cc1F)N1CC(O)([C@@H]2CCCCN2)C1 |
PDB | — |
CAS-ID | 934660-93-2 |
RxCUI | — |
ChEMBL ID | CHEMBL2146883 |
ChEBI ID | — |
PubChem CID | 16222096 |
DrugBank | DB05239 |
UNII ID | ER29L26N1X (ChemIDplus, GSRS) |